Sana Biotechnology Announces Publication in New England Journal of Medicine

Globenewswire
Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes

Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection

Six-Month Patient Follow-up Results Presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions Further Demonstrate that Sana’s HIP-Modified Pancreatic Islet Cells are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient
snip
https://www.globenewswire.com/news-release/2025/08/04/3126728/0/en/Sana-Biotechnology-Announces-Publication-in-New-England-Journal-of-Medicine-of-Groundbreaking-Clinical-Data-from-Transplantation-Without-Immunosuppression-of-Hypoimmune-Modified-In.html